Evaluation of ketamine HCl for anti-depressant activity.
Using several routine screening procedures to determine anti-depressant drug activity in experimental laboratory animals, ketamine HCl was found to possess significant activity over a wide-range of oral doses. The tests used were (a) reversal of tetrabenazine-induced ptosis in mice, (b) reversal of reserpine-induced hypothermia in rats, (c) enhancement of yohimbine toxicity in mice and (d) inhibition of oxotremorine-induced tremors in mice. In general, the anti-depressant potency of ketamine HCl was substantially less than that of imipramine HCl.
D000818:Animals; D000928:Antidepressive Agents / Q000494:pharmacology*; D001763:Blepharoptosis / Q000139:chemically induced*; D001831:Body Temperature / Q000187:drug effects; D004357:Drug Synergism; D007099:Imipramine / Q000494:pharmacology; D007649:Ketamine / Q000494:pharmacology*; D008297:Male; D051379:Mice; D010095:Oxotremorine / Q000037:antagonists & inhibitors; D010276:Parasympatholytics / Q000494:pharmacology; D051381:Rats; D012110:Reserpine / Q000494:pharmacology; D013747:Tetrabenazine / Q000037:antagonists & inhibitors; D015016:Yohimbine / Q000633:toxicity
D000928:Antidepressive Agents; D010276:Parasympatholytics; D015016:Yohimbine; D010095:Oxotremorine; D007649:Ketamine; D012110:Reserpine; D007099:Imipramine; D013747:Tetrabenazine